MESO Q2 2023 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-16.9% YoY

Gross Profit

-$14M-686.7% margin

Operating Income

-$21M-1066.3% margin

Net Income

-$24M-1236.7% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+37.2%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$668M

Total Liabilities

$168M

Stockholders' Equity

$500M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-16.9%
Gross Profit	-$14M	-$14M	+5.6%
Operating Income	-$21M	-$22M	+5.0%
Net Income	-$24M	-$26M	+5.6%